Sunitinib targeted VEGFC and KDR genes by inhibiting the tyrosine kinase receptors, containing platelet-derived development factor receptors and vascular endothelial development factor receptors, which have single-agent antitumor action in intractable NSCLC [34]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.